Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biological factors that impinge on Chagas disease drug development
Amanda Fortes Francisco, Shiromani Jayawardhana, Michael D. Lewis, et al.
Parasitology (2017) Vol. 144, Iss. 14, pp. 1871-1880
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

An Updated View of the Trypanosoma cruzi Life Cycle: Intervention Points for an Effective Treatment
Javier Martín‐Escolano, Clotilde Marı́n, María J. Rosales, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 6, pp. 1107-1115
Open Access | Times Cited: 72
Protozoan persister-like cells and drug treatment failure
Michael P. Barrett, Dennis E. Kyle, L. David Sibley, et al.
Nature Reviews Microbiology (2019) Vol. 17, Iss. 10, pp. 607-620
Open Access | Times Cited: 135
The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets
Fernando Altamura, Rishi Rajesh, Carolina Moura Costa Catta‐Preta, et al.
Drug Development Research (2020) Vol. 83, Iss. 2, pp. 225-252
Closed Access | Times Cited: 77
Phenotypic screening approaches for Chagas disease drug discovery
Eric Chatelain, Jean‐Robert Ioset
Expert Opinion on Drug Discovery (2017) Vol. 13, Iss. 2, pp. 141-153
Closed Access | Times Cited: 83
The translational challenge in Chagas disease drug development
Jadel M. Kratz, Karolina Ribeiro Gonçalves, Lavínia MD Romera, et al.
Memórias do Instituto Oswaldo Cruz (2022) Vol. 117
Open Access | Times Cited: 38
Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies
Miebaka Jamabo, Maduma Ernst Mahlalela, Adrienne L. Edkins, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12529-12529
Open Access | Times Cited: 18
Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi
Alane Beatriz Vermelho, Verônica da Silva Cardoso, Eduardo Ricci‐Júnior, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2017) Vol. 33, Iss. 1, pp. 139-146
Open Access | Times Cited: 55
Synthesis of Hydrazinyl–Thiazole Ester Derivatives, in Vitro Trypanocidal and Leishmanicidal Activities
Muhammad Haroon, Tashfeen Akhtar, Hasnain Mehmood, et al.
Future Medicinal Chemistry (2024) Vol. 16, Iss. 3, pp. 221-238
Closed Access | Times Cited: 5
Animal models of Chagas disease and their translational value to drug development
Eric Chatelain, Ivan Scandale
Expert Opinion on Drug Discovery (2020) Vol. 15, Iss. 12, pp. 1381-1402
Open Access | Times Cited: 37
Further Investigations of Nitroheterocyclic Compounds as Potential Antikinetoplastid Drug Candidates
Carlos García‐Estrada, Yolanda Pérez‐Pertejo, Bárbara Domínguez-Asenjo, et al.
Biomolecules (2023) Vol. 13, Iss. 4, pp. 637-637
Open Access | Times Cited: 12
Therapeutic Interventions for Countering Leishmaniasis and Chagas’s Disease: From Traditional Sources to Nanotechnological Systems
Eliana B. Souto, João Dias-Ferreira, Sara A. Craveiro, et al.
Pathogens (2019) Vol. 8, Iss. 3, pp. 119-119
Open Access | Times Cited: 35
Chagas Disease: Current View of an Ancient and Global Chemotherapy Challenge
Javier Martín‐Escolano, Encarnación Medina‐Carmona, Rubén Martín‐Escolano
ACS Infectious Diseases (2020) Vol. 6, Iss. 11, pp. 2830-2843
Closed Access | Times Cited: 31
Trypanosoma cruzi amastigotes that persist in the colon during chronic stage murine infections have a reduced replication rate
Alexander I. Ward, Francisco Olmo, Richard L. Atherton, et al.
Open Biology (2020) Vol. 10, Iss. 12
Open Access | Times Cited: 31
Intracellular DNA replication and differentiation of Trypanosoma cruzi is asynchronous within individual host cells in vivo at all stages of infection
Martin C. Taylor, Alexander I. Ward, Francisco Olmo, et al.
PLoS neglected tropical diseases (2020) Vol. 14, Iss. 3, pp. e0008007-e0008007
Open Access | Times Cited: 30
Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease
Amanda Fortes Francisco, Shiromani Jayawardhana, Martin C. Taylor, et al.
Antimicrobial Agents and Chemotherapy (2018) Vol. 62, Iss. 10
Open Access | Times Cited: 29
Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' Disease
Juan Felipe Osorio-Méndez, Ana Marı́a Cevallos
Frontiers in Cellular and Infection Microbiology (2019) Vol. 8
Open Access | Times Cited: 28
Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice
Victor Manuel Dzul-Huchim, María Jesús Ramírez-Sierra, Pedro Pablo Martínez-Vega, et al.
PLoS neglected tropical diseases (2022) Vol. 16, Iss. 9, pp. e0010258-e0010258
Open Access | Times Cited: 15
A Rapid Review on the Efficacy and Safety of Pharmacological Treatments for Chagas Disease
Cody J. Malone, Immaculate Nevis, Eduardo A Fernández C, et al.
Tropical Medicine and Infectious Disease (2021) Vol. 6, Iss. 3, pp. 128-128
Open Access | Times Cited: 20
Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi
Cristina Fonseca‐Berzal, Vicente J. Arán, José Antonio Escario, et al.
Parasitology Research (2018) Vol. 117, Iss. 11, pp. 3367-3380
Closed Access | Times Cited: 22
Exploiting Genetically Modified Dual-Reporter Strains to Monitor Experimental Trypanosoma cruzi Infections and Host-Parasite Interactions
Martin C. Taylor, Amanda Fortes Francisco, Shiromani Jayawardhana, et al.
Methods in molecular biology (2019), pp. 147-163
Closed Access | Times Cited: 22
Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy
Andrew M. Thompson, P. D. T. O’Connor, Andrew J. Marshall, et al.
European Journal of Medicinal Chemistry (2020) Vol. 207, pp. 112849-112849
Open Access | Times Cited: 19
Anti-Trypanosoma cruzi Activity of Metabolism Modifier Compounds
Nieves Martínez-Peinado, Clara Martori, Núria Cortes-Serra, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 688-688
Open Access | Times Cited: 17
Dynamics of the Trypanosoma cruzi infection in adipose tissue: Assessing gene expression of PNPLA2, FASN, and ACAT1 under Benzonidazole treatment and indirect mononuclear immune cells interaction
Ana Carla da Silva, Leyllane Rafael Moreira, Cíntia Nascimento da Costa Oliveira, et al.
Molecular and Biochemical Parasitology (2024) Vol. 258, pp. 111618-111618
Open Access | Times Cited: 2
Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
Shiromani Jayawardhana, Alexander I. Ward, Amanda Fortes Francisco, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 11, pp. e1011627-e1011627
Open Access | Times Cited: 6
Drug-cured experimental Trypanosoma cruzi infections confer long-lasting and cross-strain protection
Gurdip Singh Mann, Amanda Fortes Francisco, Shiromani Jayawardhana, et al.
PLoS neglected tropical diseases (2020) Vol. 14, Iss. 4, pp. e0007717-e0007717
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top